Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pierre Fabre, Addex Sign Early-Stage CNS Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pierre Fabre, Addex Sign Early-Stage CNS Agreement

Pierre Fabre will conduct chemistry, pharmacology and ADME

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Addex Therapeutics, a company involved in allosteric modulation-based drug discovery and development, has granted an option to license its metabotropic glutamate receptor subtype 3 (mGlu3 receptor) program to Pierre Fabre Pharmaceuticals, a laboratory with a track-record in discovering, developing and marketing products in the field of central nervous system (CNS).

“This agreement confirms our strong and continued interest in the CNS field to develop therapies addressing critical global health problems,” said Laurent Audoly, head of Pierre Fabre Pharmaceuticals R&D. “Pierre Fabre is committed to developing such early stage collaborations to capitalize on its long-standing preclinical and clinical experience in the CNS field to create value and win-win scenarios with our partners.”

“We are delighted to be working with Pierre Fabre and their CNS discovery group which has a strong track record in CNS drug discovery,” said Robert Lütjens, head of discovery, Addex. “mGlu3 receptor represents an exciting novel target and we look forward to rapidly advancing this program.”

“This agreement represents a strong validation of our discovery platform and highlights the value of Addex’ proprietary expertise in allosteric modulator drug discovery,” said Tim Dyer, chief executive officer, Addex. “This agreement is another example of our strategy to advance our preclinical programs through collaboration with industry.”

Using its proprietary allosteric modulator discovery platform, Addex has been able to identify unique mGlu3 receptor positive and negative allosteric modulators. These compounds, although still at an early stage, represent excellent starting points for chemical optimization, and have a great potential to become first-in-class molecules useful for the treatment of CNS disorders involving an imbalance in mGlu3 receptor signalling. Under the terms of the agreement, Pierre Fabre will conduct chemistry, pharmacology and ADME, while Addex will support the project with its proprietary in vitro pharmacological assay platform.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics